977 related articles for article (PubMed ID: 12876551)
1. [Mechanisms of action of antidepressants: new data from Escitalopram].
Fabre V; Hamon M
Encephale; 2003; 29(3 Pt 1):259-65. PubMed ID: 12876551
[TBL] [Abstract][Full Text] [Related]
2. [Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].
Mnie-Filali O; El Mansari M; Scarna H; Zimmer L; Sánchez C; Haddjeri N
Encephale; 2007 Dec; 33(6):965-72. PubMed ID: 18789789
[TBL] [Abstract][Full Text] [Related]
3. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.
Sánchez C; Bergqvist PB; Brennum LT; Gupta S; Hogg S; Larsen A; Wiborg O
Psychopharmacology (Berl); 2003 Jun; 167(4):353-62. PubMed ID: 12719960
[TBL] [Abstract][Full Text] [Related]
4. Blockade of the high-affinity noradrenaline transporter (NET) by the selective 5-HT reuptake inhibitor escitalopram: an in vivo microdialysis study in mice.
Nguyen HT; Guiard BP; Bacq A; David DJ; David I; Quesseveur G; Gautron S; Sanchez C; Gardier AM
Br J Pharmacol; 2013 Jan; 168(1):103-16. PubMed ID: 22233336
[TBL] [Abstract][Full Text] [Related]
5. Escitalopram: a unique mechanism of action.
Bræstrup C; Sanchez C
Int J Psychiatry Clin Pract; 2004; 8 Suppl 1():11-3. PubMed ID: 24930683
[TBL] [Abstract][Full Text] [Related]
6. The R-enantiomer of citalopram counteracts escitalopram-induced increase in extracellular 5-HT in the frontal cortex of freely moving rats.
Mørk A; Kreilgaard M; Sánchez C
Neuropharmacology; 2003 Aug; 45(2):167-73. PubMed ID: 12842122
[TBL] [Abstract][Full Text] [Related]
7. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
Mansari ME; Wiborg O; Mnie-Filali O; Benturquia N; Sánchez C; Haddjeri N
Int J Neuropsychopharmacol; 2007 Feb; 10(1):31-40. PubMed ID: 16448580
[TBL] [Abstract][Full Text] [Related]
8. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine.
Owens MJ; Knight DL; Nemeroff CB
Biol Psychiatry; 2001 Sep; 50(5):345-50. PubMed ID: 11543737
[TBL] [Abstract][Full Text] [Related]
9. Hypobaric hypoxia exposure in rats differentially alters antidepressant efficacy of the selective serotonin reuptake inhibitors fluoxetine, paroxetine, escitalopram and sertraline.
Kanekar S; Sheth CS; Ombach HJ; Olson PR; Bogdanova OV; Petersen M; Renshaw CE; Sung YH; D'Anci KE; Renshaw PF
Pharmacol Biochem Behav; 2018 Jul; 170():25-35. PubMed ID: 29738811
[TBL] [Abstract][Full Text] [Related]
10. Behavioral profiles of SSRIs in animal models of depression, anxiety and aggression. Are they all alike?
Sánchez C; Meier E
Psychopharmacology (Berl); 1997 Feb; 129(3):197-205. PubMed ID: 9084057
[TBL] [Abstract][Full Text] [Related]
11. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram.
Sánchez C; Kreilgaard M
Pharmacol Biochem Behav; 2004 Feb; 77(2):391-8. PubMed ID: 14751469
[TBL] [Abstract][Full Text] [Related]
12. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model.
Sánchez C; Gruca P; Papp M
Behav Pharmacol; 2003 Sep; 14(5-6):465-70. PubMed ID: 14501259
[TBL] [Abstract][Full Text] [Related]
13. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike?
Sanchez C; Reines EH; Montgomery SA
Int Clin Psychopharmacol; 2014 Jul; 29(4):185-96. PubMed ID: 24424469
[TBL] [Abstract][Full Text] [Related]
14. Escitalopram.
Aronson S; Delgado P
Drugs Today (Barc); 2004 Feb; 40(2):121-31. PubMed ID: 15045034
[TBL] [Abstract][Full Text] [Related]
15. Escitalopram : a review of its use in the management of major depressive and anxiety disorders.
Waugh J; Goa KL
CNS Drugs; 2003; 17(5):343-62. PubMed ID: 12665392
[TBL] [Abstract][Full Text] [Related]
16. 17β-Estradiol augments antidepressant efficacy of escitalopram in ovariectomized rats: Neuroprotective and serotonin reuptake transporter modulatory effects.
Ibrahim WW; Safar MM; Khattab MM; Agha AM
Psychoneuroendocrinology; 2016 Dec; 74():240-250. PubMed ID: 27685339
[TBL] [Abstract][Full Text] [Related]
17. Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups.
Fish EW; Faccidomo S; Gupta S; Miczek KA
J Pharmacol Exp Ther; 2004 Feb; 308(2):474-80. PubMed ID: 14593091
[TBL] [Abstract][Full Text] [Related]
18. [Escitalopram is more effective than citalopram for the treatment of severe major depressive disorder].
Azorin JM; Llorca PM; Despiegel N; Verpillat P
Encephale; 2004; 30(2):158-66. PubMed ID: 15107719
[TBL] [Abstract][Full Text] [Related]
19. Effects of selective serotonin and serotonin/noradrenaline reuptake inhibitors on extracellular serotonin in rat diencephalon and frontal cortex.
Felton TM; Kang TB; Hjorth S; Auerbach SB
Naunyn Schmiedebergs Arch Pharmacol; 2003 Mar; 367(3):297-305. PubMed ID: 12644903
[TBL] [Abstract][Full Text] [Related]
20. S 15535, a novel benzodioxopiperazine ligand of serotonin (5-HT)1A receptors: I. Interaction with cloned human (h)5-HT1A, dopamine hD2/hD3 and h alpha2A-adrenergic receptors in relation to modulation of cortical monoamine release and activity in models of potential antidepressant activity.
Millan MJ; Newman-Tancredi A; Rivet JM; Brocco M; Lacroix P; Audinot V; Cistarelli L; Gobert A
J Pharmacol Exp Ther; 1997 Jul; 282(1):132-47. PubMed ID: 9223549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]